ZBIO PRESS-RELEASE SEC Filing Analysis

Latest settled — T+5d ⚠ clustered

ZBIO ▼ -10.49% at T+5d

NEUTRAL call ✗ call lost -10.49% · α vs SPY -9.33% · entry $19.93 → $17.84

Next anchor: T+20d tomorrow

Last close $17.61 (close Jun 8) · -11.64% from $19.93 entry

Entry anchored
May 12, 03:59 PM ET
via Databento tick

T+1d

-5.17%

call -5.17% · α -5.95%

$18.90

settled 27d ago

T+5d

-10.49%

call -10.49% · α -9.33%

$17.84

settled 21d ago

T+20d

—

call — · α —

—

tomorrow

T+60d

—

call — · α —

—

in 8w

Price Chart

Loading chart...

Executive Summary

Zenas BioPharma announced first subject dosed in Phase 1 trial of ZB021, an oral IL-17AA/AF inhibitor for autoimmune diseases. This is an early-stage pipeline milestone with no clinical data yet; initial results expected by year-end 2026 and proof-of-concept in psoriasis patients in 2027.

Actionable Insight

This is a very early-stage pipeline event with no clinical data yet. The stock may see modest interest given the novelty of an oral IL-17 inhibitor, but significant catalysts are 6-12+ months away. Monitor for Phase 1 data readout by year-end 2026.

Key Facts

First subject dosed in Phase 1 trial of ZB021, a novel oral IL-17AA/AF inhibitor
Phase 1 SAD/MAD data expected by year-end 2026
Proof-of-concept data in psoriasis patients anticipated in 2027
No oral IL-17 inhibitors are currently approved or in late-stage development globally
Zenas licensed exclusive rights from InnoCare Pharma for ZB021 outside greater China and Southeast Asia

Financial Impact

No financial data disclosed; early clinical-stage milestone with no revenue impact

Risk Factors

Phase 1 trial may fail to show adequate safety or efficacy
Competition from approved biologic IL-17 therapies (e.g., secukinumab, ixekizumab)
Dependence on partnership with InnoCare Pharma in China
Zenas has no approved products and requires substantial additional financing

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

86% bullish (14 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3293817

12 reports for ZBIO

T+1T+5T+20T+60

75% Hit rate 3 of 4 directional calls best @ T+5▲ +22.24%Mar 26, 2026

Filters

Reports for ZBIO — sortable, filterable
	Type				Now
May 28, 2026 12d ago	Press Release BULLISH ★ 7/10	$18.56 $18.38	▼ −0.97%	▼ −1.29%	$17.61 (−5.12%)
May 19, 2026 21d ago	Press Release BULLISH ★ 7/10	$17.84 $18.53	▲ +3.84%	▲ +1.59%	$17.61 (−1.29%)
May 13, 2026 27d ago	Press Release NEUTRAL ★ 4/10	$19.93 $17.84	▼ −10.49%	▼ −9.33%	$17.61 (−11.64%)
May 13, 2026 27d ago	8-K NEUTRAL ★ 4/10	$19.93 $17.84	▼ −10.49%	▼ −9.33%	$17.61 (−11.64%)
May 13, 2026 27d ago	Press Release NEUTRAL ★ 5/10	$19.93 $17.84	▼ −10.49%	▼ −9.33%	$17.61 (−11.64%)
Mar 31, 2026 10w ago	Insider Cluster MIXED ★ 6/10	$19.55 $20.86	▲ +6.70%	▲ +2.76%	$17.61 (−9.92%)
Mar 27, 2026 10w ago	Press Release NEUTRAL ★ 6/10	$18.21 $22.26	▲ +22.24%	▲ +18.38%	$17.61 (−3.29%)
Mar 26, 2026 10w ago	424B5 MIXED ★ 6/10	$18.21 $22.26	▲ +22.24%	▲ +18.38%	$17.61 (−3.29%)
Mar 26, 2026 10w ago	424B5 BULLISH ★ 7/10	$18.21 $22.26	▲ +22.24%	▲ +18.38%	$17.61 (−3.29%)
Mar 16, 2026 12w ago	DEFA14A NEUTRAL ★ 2/10	$23.23 $20.63	▼ −11.19%	▼ −9.15%	$17.61 (−24.19%)

US Market Status

Market Closed — Opens in 8h 32m

Related Tickers

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access